Reaction Biology Corporation

reactionbiology.com

Reaction Biology Corp. (“RBC”) is a premier service provider for drug profiling, screening and early-stage drug discovery collaborations. Its proprietary HotSpot technology is an innovative platform for screening/profiling small molecules vs biological target assayable by radioisotope detection. For kinase and transferase enzymes in particular, such assays are the “gold standard”. RBC screens and profiles vs all major classes of epigenetic transferases via the radioisotope approach—HMTs, DNMTs, HATs, and also over 600 kinases. HotSpot assay substrates require no special modifications (e.g. biotin, fluorophors or other tags). Hence biologically relevant substrates may be used, including full nucleosomes, histone proteins or peptides. Since detection does not rely on antibodies, coupling enzymes or fluorescence, major causes of false positives, false negatives and compound interference are eliminated.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BAY AREA BIOTECH INCUBATOR OPENS EXTENSIVE NEW LAB FACILITY, PAVING WAY FOR ENTREPRENEURS AND THEIR INNOVATION

MBC BioLabs | May 11, 2020

news image

Innovation and discovery just got easier for life science entrepreneurs as MBC BioLabs announces the opening of a 30,000 square foot building of incubator lab space in San Carlos, Calif.Built specifically as a life-science incubator space over the past 18 months, the new facility brings cutting-edge lab equipment, infrastructure and services to innovators and entrepreneurs so they can begin their discovery work virtually immediately. This is MBC BioLabs' third campus and its seco...

Read More

INDUSTRIAL IMPACT

ORION BIOTECHNOLOGY AND PEPTILOGICS ENTER STRATEGIC RESEARCH COLLABORATION TO ENABLE AI-DRIVEN DRUG DISCOVERY AGAINST UNDRUGGED GPCR TARGET

Orion Biotechnology | July 15, 2022

news image

Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target. The collaboration will combine the...

Read More

ECOGEN LABORATORIES ANNOUNCES OPERATIONAL UPDATE AMID COVID-19 PANDEMIC

BioSpace | March 20, 2020

news image

EcoGen Laboratories ("EcoGen"), the leading vertically-integrated manufacturer and supplier of high quality hemp genetics, hemp-derived specialty ingredients and finished products in North America, released the following statement today from the Company's Co-Founder and CEO Alexis Korybut regarding operational updates amid the COVID-19 pandemic....

Read More

CELL AND GENE THERAPY

TEVOGEN BIO™ FURTHER STRENGTHENS IP PORTFOLIO WITH ADDITIONAL PATENT FOR METHOD OF PREPARING ITS INVESTIGATIONAL SARS-COV-2 SPECIFIC T CELL THERAPY

Tevogen Bio | January 13, 2022

news image

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, announced that the U.S. Patent and Trademark Office has granted a new patent for the method of preparing COVID-19 peptide specific cytotoxic T cells for the treatment of COVID-19 infection. The patent further reinforces the biotech pioneer’s expanding IP portfolio. “Omicron’s extensive mutations and its subsequent abi...

Read More
news image

BAY AREA BIOTECH INCUBATOR OPENS EXTENSIVE NEW LAB FACILITY, PAVING WAY FOR ENTREPRENEURS AND THEIR INNOVATION

MBC BioLabs | May 11, 2020

Innovation and discovery just got easier for life science entrepreneurs as MBC BioLabs announces the opening of a 30,000 square foot building of incubator lab space in San Carlos, Calif.Built specifically as a life-science incubator space over the past 18 months, the new facility brings cutting-edge lab equipment, infrastructure and services to innovators and entrepreneurs so they can begin their discovery work virtually immediately. This is MBC BioLabs' third campus and its seco...

Read More
news image

INDUSTRIAL IMPACT

ORION BIOTECHNOLOGY AND PEPTILOGICS ENTER STRATEGIC RESEARCH COLLABORATION TO ENABLE AI-DRIVEN DRUG DISCOVERY AGAINST UNDRUGGED GPCR TARGET

Orion Biotechnology | July 15, 2022

Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target. The collaboration will combine the...

Read More
news image

ECOGEN LABORATORIES ANNOUNCES OPERATIONAL UPDATE AMID COVID-19 PANDEMIC

BioSpace | March 20, 2020

EcoGen Laboratories ("EcoGen"), the leading vertically-integrated manufacturer and supplier of high quality hemp genetics, hemp-derived specialty ingredients and finished products in North America, released the following statement today from the Company's Co-Founder and CEO Alexis Korybut regarding operational updates amid the COVID-19 pandemic....

Read More
news image

CELL AND GENE THERAPY

TEVOGEN BIO™ FURTHER STRENGTHENS IP PORTFOLIO WITH ADDITIONAL PATENT FOR METHOD OF PREPARING ITS INVESTIGATIONAL SARS-COV-2 SPECIFIC T CELL THERAPY

Tevogen Bio | January 13, 2022

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, announced that the U.S. Patent and Trademark Office has granted a new patent for the method of preparing COVID-19 peptide specific cytotoxic T cells for the treatment of COVID-19 infection. The patent further reinforces the biotech pioneer’s expanding IP portfolio. “Omicron’s extensive mutations and its subsequent abi...

Read More